pexelizumab
Jump to navigation
Jump to search
Indications
* percutaneous transluminal coronary intervention (PCI) ST-segment-elevation myocardial infarction (STEMI)
Dosage
2-mg/kg bolus, the 0.05-mg/kg/hour infusion for 24 hours
Mechanism of action
- binds complement C5
- near-complete inhibition of complement activity for 24 hours (with therapeutic dose)
- anti-inflammatory actions
More general terms
References
- ↑ 1.0 1.1 APEX AMI Investigators; Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, Todaro TG, Vahanian A, Van de Werf F. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007 Jan 3;297(1):43-51. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17200474
Eikelboom JW, O'Donnell M. Pexelizumab does not 'complement' percutaneous coronary intervention in patients with ST-elevation myocardial infarction. JAMA. 2007 Jan 3;297(1):91-2. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17200480